Bladder Transitional Cell Carcinoma Stage IV (DBCOND0057636)
Identifiers
- Synonyms
- Bladder transitional cell carcinoma stage IV / Urothelial carcinoma bladder stage IV / Transitional cell carcinoma of the bladder stage IV
Associated Data
- Indicated Drugs and Targets
Drug Description Targets Gemcitabine A nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer.- Ribonucleoside-diphosphate reductase large subunittarget
- UMP-CMP kinasetarget
- Thymidylate synthasetarget
- Cytidine deaminaseenzyme
- Deoxycytidine kinaseenzyme
- ATP-dependent translocase ABCB1transporter
- ATP-binding cassette sub-family C member 10transporter
- Equilibrative nucleoside transporter 1transporter
- DNAtarget
- Sodium/nucleoside cotransporter 1transporter
- Equilibrative nucleoside transporter 2transporter
- Solute carrier family 28 member 3transporter
- Thymidine kinase 2, mitochondrialenzyme
- UMP-CMP kinaseenzyme
- Nucleoside diphosphate kinase Aenzyme
- Ribonucleoside-diphosphate reductase subunit M2target
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT01599013 JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin treatment 2 completed